(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1550126

経口高分子製剤市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Oral Macromolecular Formulation Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 158 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
経口高分子製剤市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年09月05日
発行: Persistence Market Research
ページ情報: 英文 158 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界の経口高分子製剤市場に関する広範なレポートを発行しました。当レポートでは、促進要因・動向・機会・課題などの主要な市場力学を包括的に分析し、市場構造に関する深い洞察を提供しています。

主要な洞察

  • 経口高分子製剤の市場規模（2024年）：1,890万米ドル
  • 予測市場金額（2033年）：2,920万米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：5.0%

経口高分子製剤市場 - レポート範囲：

経口高分子製剤市場には、高分子治療薬の経口投与を可能にするさまざまな技術や方法が含まれます。タンパク質、ペプチド、核酸を含む高分子医薬品は、従来、消化管での分解や吸収率の低さから経口投与に課題を抱えていました。しかし、近年の製剤技術の進歩により、注射のような侵襲的な方法と比較して患者のコンプライアンスが向上する経口投与へのシフトが進んでいます。同市場は、糖尿病、腫瘍、免疫学など幅広い治療領域に対応しています。

市場成長の促進要因：

世界の経口高分子製剤市場を牽引する要因はいくつかあります。主要な促進要因の1つは、患者に優しいドラッグデリバリー方法に対する需要の高まりです。高分子医薬品が慢性疾患の治療に普及するにつれ、患者の服薬アドヒアランスとQOLを向上させるため、注射剤から経口剤への移行ニーズが高まっています。浸透促進剤、酵素阻害剤、ナノテクノロジーなどの製剤・送達技術の技術的進歩により、経口経路における高分子の安定性とバイオアベイラビリティが大幅に改善されています。さらに、消化管分解など経口高分子ドラッグデリバリーの障壁を克服することに焦点を当てた研究開発活動の活発化が、市場の成長を促進すると予想されます。

市場抑制要因：

有望な成長見通しにもかかわらず、経口高分子製剤市場はいくつかの課題に直面しています。経口高分子製剤の開発・製造に関連する高コストは、特に中小製薬企業にとって市場参入の大きな障壁となっています。さらに、高分子製剤の一貫した効果的な経口バイオアベイラビリティを達成するための技術的困難が、これらの治療法の普及を制限しています。また、新規の経口高分子製剤を承認するための規制上のハードルも、安全性と有効性の確保が複雑であることから、市場成長の課題となっています。

市場機会：

経口高分子製剤市場は、非侵襲的な治療オプションに対する需要の拡大により、大きな成長機会を提供しています。ナノ粒子ベースのキャリアや高度なプロドラッグ戦略などの革新的なドラッグデリバリープラットフォームの開発は、経口高分子ドラッグデリバリーの限界を克服する潜在的な解決策を提供します。さらに、特に新興市場において慢性疾患の蔓延が拡大していることから、ヘルスケアへのアクセスや非侵襲的治療に対する患者の選好が原動力となっている地域において、製薬企業が経口高分子製剤を導入する機会が生まれています。新技術を開発するための製薬企業と学術研究機関との戦略的提携も、こうした機会を生かす上で極めて重要な役割を果たすと思われます。

本レポートで扱う主要な質問

  • 経口高分子製剤市場の世界の成長を促進する主要な要因は何か？
  • 市場をリードしているのはどのような種類の技術と製剤化技術か？
  • 技術の進歩は経口高分子製剤市場の競合情勢にどのような影響を与えているか？
  • 経口高分子製剤市場の主要企業はどこか、また競争力を維持するためにどのような戦略をとっているのか？
  • 世界の経口高分子製剤市場の新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • イノベーション / 開発動向

第4章 主要な成功要因

  • 採用分析
  • 疾病疫学
  • 主要な規制
  • PESTEL分析
  • 主要なプロモーション戦略：主要企業別

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 適応症別
    • エンドユーザー別
    • 国別
  • 2022年の市場シナリオ

第7章 世界の経口高分子製剤市場の需要（金額または規模、百万米ドル）分析

  • 過去の市場金額（百万米ドル）分析、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の経口高分子製剤市場分析、適応症別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）の分析、適応症別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測、適応症別、2024年～2033年
    • 炎症性腸疾患
    • 糖尿病
    • その他
  • 市場の魅力分析：適応症別

第9章 世界の経口高分子製剤市場分析、エンドユーザー別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）分析、エンドユーザー別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測、エンドユーザー別、2024年～2033年
    • バイオ医薬品企業
    • 学術・研究機関
  • 市場の魅力分析：エンドユーザー別

第10章 世界の経口高分子製剤市場分析、地域別

  • イントロダクション
  • 過去の市場規模（百万米ドル）の分析、地域別、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）の分析と予測、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第11章 北米の経口高分子製剤市場分析

第12章 ラテンアメリカの経口高分子製剤市場分析

第13章 欧州の経口高分子製剤市場分析

第14章 東アジアの経口高分子製剤市場分析

第15章 南アジアの経口高分子製剤市場分析

第16章 オセアニアの経口高分子製剤市場

第17章 中東・アフリカ（MEA）の経口高分子製剤市場分析

第18章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合の詳細情報
    • Catalent, Inc
    • Diabetology Ltd
    • UPM Pharmaceuticals

第20章 使用される前提条件と頭字語

第21章 調査手法

目次
Product Code: PMRREP32388

Persistence Market Research has recently published an extensive report on the global Oral Macromolecular Formulation Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Oral Macromolecular Formulation Market Size (2024E): USD 18.9 Million
  • Projected Market Value (2033F): USD 29.2 Million
  • Global Market Growth Rate (CAGR 2024 to 2033): 5.0%

Oral Macromolecular Formulation Market - Report Scope:

The Oral Macromolecular Formulation Market encompasses a range of technologies and methods that allow for the oral delivery of large molecule therapeutics. Macromolecular drugs, which include proteins, peptides, and nucleic acids, traditionally face challenges in being delivered orally due to degradation in the gastrointestinal tract and poor absorption. However, recent advancements in formulation technologies are driving the shift toward oral administration, which improves patient compliance compared to invasive methods like injections. The market serves a wide range of therapeutic areas, including diabetes, oncology, and immunology.

Market Growth Drivers:

Several factors drive the global Oral Macromolecular Formulation Market. One of the major drivers is the increasing demand for patient-friendly drug delivery methods. As macromolecular drugs become more prevalent in treating chronic diseases, there is a growing need to transition from injectable forms to oral formulations to improve patient adherence and quality of life. Technological advancements in formulation and delivery technologies, such as permeation enhancers, enzyme inhibitors, and nanotechnology, have significantly improved the stability and bioavailability of macromolecules in the oral route. Additionally, increased research and development activities focused on overcoming the barriers to oral macromolecular drug delivery, such as gastrointestinal degradation, are expected to fuel market growth.

Market Restraints:

Despite the promising growth outlook, the Oral Macromolecular Formulation Market faces several challenges. The high costs associated with the development and manufacturing of oral macromolecular formulations pose a significant barrier to market entry, especially for smaller pharmaceutical companies. Moreover, the technical difficulties in achieving consistent and effective oral bioavailability for large molecules limit the widespread adoption of these therapies. The regulatory hurdles for approving novel oral macromolecular formulations, given the complexity of ensuring their safety and efficacy, also present challenges for market growth.

Market Opportunities:

The Oral Macromolecular Formulation Market offers significant growth opportunities due to the expanding demand for non-invasive therapeutic options. The development of innovative drug delivery platforms, such as nanoparticle-based carriers and advanced prodrug strategies, offers potential solutions for overcoming the limitations of oral macromolecular drug delivery. Additionally, the growing prevalence of chronic diseases, particularly in emerging markets, creates opportunities for pharmaceutical companies to introduce oral macromolecular formulations in regions where access to healthcare and patient preference for non-invasive treatments are driving factors. Strategic collaborations between pharmaceutical companies and academic research institutions to develop new technologies will also play a pivotal role in capitalizing on these opportunities.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Oral Macromolecular Formulation Market globally?
  • Which types of technologies and formulation techniques are leading the market?
  • How are technological advancements influencing the competitive landscape of the Oral Macromolecular Formulation Market?
  • Who are the key players in the Oral Macromolecular Formulation Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Oral Macromolecular Formulation Market?

Competitive Intelligence and Business Strategy:

Key players in the global Oral Macromolecular Formulation Market, including Novo Nordisk, Biocon, and Oramed Pharmaceuticals, focus on innovation, strategic partnerships, and product differentiation to gain a competitive edge. Companies are investing in research and development (R&D) to create new drug delivery technologies and to enhance the stability and absorption of macromolecular drugs when administered orally. Collaborations with research institutions and technology providers facilitate the development of innovative products, while strategic mergers and acquisitions allow companies to expand their market presence. Furthermore, patient-centered approaches and efforts to educate healthcare professionals about the benefits of oral macromolecular formulations will continue to foster market growth.

Key Companies Profiled:

  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

Oral Macromolecular Formulation Market Industry Segmentation

Indication:

  • Inflammatory Bowel Disorder
  • Diabetes
  • Others

End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Adoption Analysis
  • 4.2. Disease Epidemiology
  • 4.3. Key Regulations
  • 4.4. PESTEL Analysis
  • 4.5. Key Promotional Strategies, By Key Players

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Oral Proteins and Peptides Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Disease Prevalence
    • 5.2.3. Cost of Formulations
    • 5.2.4. Growing Demand in Biopharma Firms
    • 5.2.5. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Indication
    • 6.1.2. By End User
    • 6.1.3. By Country
  • 6.2. 2022 Market Scenario

7. Global Oral Macromolecule Formulation Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2033
    • 8.3.1. Inflammatory Bowel Disorder
      • 8.3.1.1. Crohn's Disease
      • 8.3.1.2. Ulcerative Colitis
    • 8.3.2. Diabetes
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis By Indication

9. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By End User

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2033
    • 9.3.1. Biopharmaceutical Companies
    • 9.3.2. Academic and Research Institutes
  • 9.4. Market Attractiveness Analysis By End User

10. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Indication
    • 11.3.3. By End User
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Indication
    • 11.4.3. By End User
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Oral Macromolecule Formulation Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Indication
        • 11.8.1.2.2. By End User
    • 11.8.2. Canada Oral Macromolecule Formulation Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Indication
        • 11.8.2.2.2. By End User

12. Latin America Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Indication
    • 12.3.3. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Indication
    • 12.4.3. By End User
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Oral Macromolecule Formulation Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Indication
        • 12.8.1.2.2. By End User
    • 12.8.2. Brazil Oral Macromolecule Formulation Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Indication
        • 12.8.2.2.2. By End User
    • 12.8.3. Argentina Oral Macromolecule Formulation Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Indication
        • 12.8.3.2.2. By End User

13. Europe Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Indication
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Indication
    • 13.4.3. By End User
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Oral Macromolecule Formulation Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Indication
        • 13.8.1.2.2. By End User
    • 13.8.2. Italy Oral Macromolecule Formulation Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Indication
        • 13.8.2.2.2. By End User
    • 13.8.3. France Oral Macromolecule Formulation Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Indication
        • 13.8.3.2.2. By End User
    • 13.8.4. U.K. Oral Macromolecule Formulation Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Indication
        • 13.8.4.2.2. By End User
    • 13.8.5. Spain Oral Macromolecule Formulation Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Indication
        • 13.8.5.2.2. By End User
    • 13.8.6. BENELUX Oral Macromolecule Formulation Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Indication
        • 13.8.6.2.2. By End User
    • 13.8.7. Russia Oral Macromolecule Formulation Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Indication
        • 13.8.7.2.2. By End User

14. East Asia Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Indication
    • 14.3.3. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Indication
    • 14.4.3. By End User
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Oral Macromolecule Formulation Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Indication
        • 14.8.1.2.2. By End User
    • 14.8.2. Japan Oral Macromolecule Formulation Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Indication
        • 14.8.2.2.2. By End User
    • 14.8.3. South Korea Oral Macromolecule Formulation Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Indication
        • 14.8.3.2.2. By End User

15. South Asia Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Indication
    • 15.3.3. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Indication
    • 15.4.3. By End User
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Oral Macromolecule Formulation Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Indication
        • 15.8.1.2.2. By End User
    • 15.8.2. Indonesia Oral Macromolecule Formulation Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Indication
        • 15.8.2.2.2. By End User
    • 15.8.3. Malaysia Oral Macromolecule Formulation Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Indication
        • 15.8.3.2.2. By End User
    • 15.8.4. Thailand Oral Macromolecule Formulation Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Indication
        • 15.8.4.2.2. By End User

16. Oceania Oral Macromolecule Formulation Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Indication
    • 16.3.3. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Indication
    • 16.4.3. By End User
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Oral Macromolecule Formulation Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Indication
        • 16.8.1.2.2. By End User
    • 16.8.2. New Zealand Oral Macromolecule Formulation Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Indication
        • 16.8.2.2.2. By End User

17. Middle East and Africa (MEA) Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Indication
    • 17.3.3. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Indication
    • 17.4.3. By End User
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Oral Macromolecule Formulation Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Indication
        • 17.8.1.2.2. By End User
    • 17.8.2. Turkey Oral Macromolecule Formulation Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Indication
        • 17.8.2.2.2. By End User
    • 17.8.3. South Africa Oral Macromolecule Formulation Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Indication
        • 17.8.3.2.2. By End User
    • 17.8.4. North Africa Oral Macromolecule Formulation Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Indication
        • 17.8.4.2.2. By End User

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Deep Dive
    • 19.2.1. Catalent, Inc
      • 19.2.1.1. Overview
      • 19.2.1.2. Portfolio
      • 19.2.1.3. Sales Footprint
      • 19.2.1.4. Key Financials
      • 19.2.1.5. SWOT Analysis
      • 19.2.1.6. Strategy Overview
        • 19.2.1.6.1. Marketing Strategy
        • 19.2.1.6.2. Channel Strategy
    • 19.2.2. Diabetology Ltd
      • 19.2.2.1. Overview
      • 19.2.2.2. Portfolio
      • 19.2.2.3. Sales Footprint
      • 19.2.2.4. Key Financials
      • 19.2.2.5. SWOT Analysis
      • 19.2.2.6. Strategy Overview
        • 19.2.2.6.1. Marketing Strategy
        • 19.2.2.6.2. Channel Strategy
    • 19.2.3. UPM Pharmaceuticals
      • 19.2.3.1. Overview
      • 19.2.3.2. Portfolio
      • 19.2.3.3. Sales Footprint
      • 19.2.3.4. Key Financials
      • 19.2.3.5. SWOT Analysis
      • 19.2.3.6. Strategy Overview
        • 19.2.3.6.1. Marketing Strategy
        • 19.2.3.6.2. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology